v3.26.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
12 Months Ended
Sep. 26, 2026
Sep. 27, 2025
Sep. 28, 2024
Statement of Cash Flows [Abstract]      
Cash, cash equivalents, and restricted cash and cash equivalents, beginning balances $ 35,934 $ 29,943 $ 30,737
Operating activities:      
Net income 132,175 112,010 93,736
Adjustments to reconcile net income to cash generated by operating activities:      
Depreciation and amortization 13,423 11,698 11,445
Share-based compensation expense 13,789 12,863 11,688
Other 568 (89) (2,266)
Changes in operating assets and liabilities:      
Accounts receivable, net (3,994) (6,682) (3,788)
Vendor non-trade receivables (6,716) (347) (1,356)
Inventories (8,905) 1,400 (1,046)
Other current and non-current assets (21,117) (9,197) (11,731)
Accounts payable 12,171 902 6,020
Other current and non-current liabilities 13,703 (11,076) 15,552
Cash generated by operating activities 145,097 111,482 118,254
Investing activities:      
Purchases of marketable securities (54,945) (24,407) (48,656)
Proceeds from maturities of marketable securities 34,815 40,907 51,211
Proceeds from sales of marketable securities 14,280 12,890 11,135
Payments for acquisition of property, plant and equipment (9,041) (12,715) (9,447)
Other (2,389) (1,480) (1,308)
Cash generated by/(used in) investing activities (17,280) 15,195 2,935
Financing activities:      
Payments for taxes related to net share settlement of equity awards (6,793) (5,960) (5,441)
Payments for dividends and dividend equivalents (15,721) (15,421) (15,234)
Repurchases of common stock (86,390) (90,711) (94,949)
Proceeds from issuance of term debt, net 0 4,481 0
Repayments of term debt (12,396) (10,932) (9,958)
Proceeds from/(Repayments of) commercial paper, net (5,911) (2,032) 3,960
Other (235) (111) (361)
Cash used in financing activities (127,446) (120,686) (121,983)
Increase/(Decrease) in cash, cash equivalents, and restricted cash and cash equivalents 371 5,991 (794)
Cash, cash equivalents, and restricted cash and cash equivalents, ending balances $ 36,305 $ 35,934 $ 29,943